Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role as caregiver. This debilitating disease reportedly consumes 8% of the total United States healthcare expenditure, with medical and nursing outlays accou...
Saved in:
Main Authors: | Hannah W Haddad, Garett W. Malone, Nicholas J. Comardelle, Arielle E. Degueure, Adam M. Kaye, Alan D. Kaye |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Medical Publishing
2022-01-01
|
Series: | Health Psychology Research |
Online Access: | https://doi.org/10.52965/001c.31925 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review
by: Hannah W. Haddad, et al.
Published: (2022-07-01) -
Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future
by: David A. Van Eijndhoven, et al.
Published: (2025-02-01) -
Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production
by: Parnian Arafi, et al.
Published: (2025-02-01) -
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
by: Alberto L. Horenstein, et al.
Published: (2025-02-01) -
Biodistribution of 89Zr-Radiolabeled Nanoassemblies for Monoclonal Antibody Delivery Revealed through In Vivo PET Imaging
by: Ana M. López-Estévez, et al.
Published: (2025-01-01)